Abstract PD15-01: Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial

Nick Turner,Estelle Roux,Eva M Ciruelos,Christina H Arce,Florence Lerebours,Hope S Rugo,Manuel Ruiz-Borrego,Thomas Bachelot,Dejan Juric,Pamela Drullinsky,Alejandro Balbin,Stephen Chia,Murat Akdere,Mukta Joshi,Aleix Prat

doi:10.1158/1538-7445.sabcs21-pd15-01

Abstract PD15-01: Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial

Nick Turner, Estelle Roux + Show 13 more

https://doi.org/10.1158/1538-7445.sabcs21-pd15-01

Copy DOI

Export

Save

Cite

Journal: Cancer Research	Publication Date: Feb 15, 2022
Citations: 5

Affiliation: Novartis (Switzerland), Hospital Universitario 12 De Octubre, Tris Pharma (United States), Institute Curie, University of California, San Francisco, Centre Léon Bérard, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Boston Biomedical Research Institute, BC Cancer Agency, University of British Columbia, Hospital Clínic de Barcelona

#Alpelisib #Prior Therapy #ESR1 Mutation #PO QD #Fulvestrant #Human Epidermal Growth Factor Receptor #Advanced Breast Cancer #Aromatase Inhibitors #Endocrine Therapy #Mo Follow-up

Abstract
Full-Text
Similar Papers

Abstract

Listen

Abstract PD15-01: Impact of <i>ESR1</i> mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Cancer Research

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime